Role of surgical intervention in the management of crotaline snake envenomation☆☆☆
To access this article, please choose from the options below
☆ Dr. Hall was a clinical investigator in the trials of the experimental antivenom described in the text and was a paid speaker in the symposium Advances in the Management of Snakebite that was sponsored by Savage Laboratories.
☆☆ Address for reprints: Edward L. Hall, MD, South Georgia Surgical Associates, PC, 100 Mimosa Drive, Thomasville, GA 31799-0520;,912-226-8881, fax 912-225-2165;,E-mail sgsa@rose.net .
PII: S0196-0644(01)43644-4
doi:10.1067/mem.2001.113373
© 2001 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Out-of-hospital and interhospital management of crotaline snakebite
- Efficacy, safety, and use of snake antivenoms in the United States
- Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies
- Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 2. Guidelines for clinical management with crotaline fab antivenom
